Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-09-16 pm EDT			5-day change	1st Jan Change
239.38 ^USD	+0.28%		-0.62%	+3.46%

Sep. 06	Veeva Systems: leader in cloud solutions for the life sciences industry
Sep. 04	'Brighter Skies' Ahead for IQVIA As EPS Set to 'Reaccelerate', RBC Capital Says	MT

Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 2013.

July 22, 2024 at 04:27 pm EDT

From April 1, 2024 to June 30, 2024, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 78,771,812 shares, representing 45.34% for $8,638.73 million under the buyback announced on October 31, 2013.

Latest news about Iqvia Holdings Inc.

Veeva Systems: leader in cloud solutions for the life sciences industry	Sep. 06
'Brighter Skies' Ahead for IQVIA As EPS Set to 'Reaccelerate', RBC Capital Says	Sep. 04	MT
Transcript : IQVIA Holdings Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 10:00 AM	Sep. 04
Signant Health Expands Availability of its eClinical Solutions by Joining IQVIA One Home for Sites Initiative	Sep. 04	CI
RBC Initiates IQVIA Holdings at Outperform With $275 Price Target	Sep. 04	MT
Iqvia Holdings Insider Sold Shares Worth $320,229, According to a Recent SEC Filing	Aug. 29	MT
Musk magic fizzles, Alphabet stumbles, and stock markets feel the blues	Jul. 24
Jefferies Downgrades IQVIA Holdings to Hold From Buy, Adjusts Price Target to $242 From $266	Jul. 24	MT
Analyst recommendations: Colgate, Lockheed Martin, Procter & Gamble, Eli Lilly, Tesla...	Jul. 24
UBS Adjusts IQVIA Holdings Price Target to $300 From $295, Maintains Buy Rating	Jul. 23	MT
HSBC Adjusts Price Target on IQVIA to $290 From $280	Jul. 23	MT
Morgan Stanley Adjusts Price Target on IQVIA Holdings to $280 From $270, Maintains Overweight Rating	Jul. 23	MT
Barclays Adjusts Price Target on IQVIA Holdings to $275 From $255, Maintains Overweight Rating	Jul. 23	MT
Goldman Sachs Adjusts Price Target on IQVIA Holdings to $280 From $270, Maintains Buy Rating	Jul. 23	MT
Baird Adjusts Price Target on IQVIA Holdings to $251 From $235, Maintains Neutral Rating	Jul. 23	MT
Evercore ISI Adjusts Price Target on IQVIA Holdings to $270 From $230, Maintains Outperform Rating	Jul. 23	MT
Truist Adjusts Price Target on IQVIA Holdings to $300 From $292, Maintains Buy Rating	Jul. 23	MT
Equities Close Higher Ahead of This Week's Major Earnings	Jul. 22	MT
Equities Close Higher Ahead of Major Earnings	Jul. 22	MT
Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 2013.	Jul. 22	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Jul. 22	MT
US Equities End Higher Monday as Markets Await Corporate Earnings	Jul. 22	MT
Stifel Adjusts IQVIA Holdings' Price Target to $312 From $288	Jul. 22	MT
Equity Markets Rise Intraday as Investors Await This Week's Major Earnings	Jul. 22	MT
Sector Update: Health Care Stocks Higher Monday Afternoon	Jul. 22	MT

Chart Iqvia Holdings Inc.

Duration

Period

More charts

Company Profile

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).

Employees

88,000

Sector

Biotechnology & Medical Research

Calendar

2024-10-29 - Q3 2024 Earnings Release (Projected)

More about the company